Aimmune Therapeutics Inc. [AIMT] fell -62.35% so far this year. What now?

Aimmune Therapeutics Inc. [NASDAQ: AIMT] jumped around 0.61 points on Friday, while shares priced at $12.60 at the close of the session, up 5.09%. The company report on August 24, 2020 that Largest European Qualitative Study on Peanut Allergy Highlights Negative Impact of Avoidance and Fear of Accidental Peanut Allergy Reactions on Allergic Individuals and Their Caregivers.

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that findings from APPEAL-2 (Allergy to Peanuts ImPacting Emotions And Life-2), the largest cross-sectional, pan-European, qualitative study to evaluate the psychosocial burden of living with peanut allergy, were published in Clinical & Experimental Allergy, the official journal of the British Society for Allergy & Clinical Immunology. The study highlights the substantial impact of peanut allergy (PA) on the lives of children, teenagers, and their caregivers. The study demonstrates how coping and management of PA are driven by fear of accidental exposure and reaction to peanut, and the resulting emotional, social, relationship, and work effects.

“In their own words, children, teens and their caregivers revealed the day-to-day difficulties of living with peanut allergy and how the lack of societal awareness impacts their emotional and social development, thereby suggesting a widespread need for improved quality of peanut allergy health management and education,” said Audrey DunnGalvin, Ph.D., an investigator on both the APPEAL-1 and APPEAL-2 projects and a lecturer in the School of Applied Psychology at University College Cork in Cork, Ireland. “These findings reinforce what we learned from the quantitative data generated from the APPEAL-1 study and provide further insight for clinicians and policymakers on the significant needs among these allergic individuals and their caregivers throughout Europe.”.

Aimmune Therapeutics Inc. stock is now -62.35% down from its year-to-date (YTD) trading value. AIMT Stock saw the intraday high of $12.68 and lowest of $11.82 per share. The company’s 52-week high price is 37.00, which means current price is +24.88% above from all time high which was touched on 01/16/20.

Compared to the average trading volume of 1.09M shares, AIMT reached a trading volume of 1810402 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about Aimmune Therapeutics Inc. [AIMT]?

Cowen have made an estimate for Aimmune Therapeutics Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on July 13, 2020. While these analysts kept the previous recommendation, H.C. Wainwright dropped their target price from $30 to $15. The new note on the price target was released on May 12, 2020, representing the official price target for Aimmune Therapeutics Inc. stock. On February 28, 2020, analysts decreased their price target for AIMT shares from 33 to 30.

The Average True Range (ATR) for Aimmune Therapeutics Inc. is set at 0.63, with the Price to Sales ratio for AIMT stock in the period of the last 12 months amounting to 1307.88. The Price to Book ratio for the last quarter was 4.57, with the Price to Cash per share for the same quarter was set at 5.04.

How has AIMT stock performed recently?

Aimmune Therapeutics Inc. [AIMT] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 0.64. With this latest performance, AIMT shares dropped by -10.26% in over the last four-week period, additionally sinking by -47.13% over the last 6 months – not to mention a drop of -34.48% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AIMT stock in for the last two-week period is set at 37.58, with the RSI for the last a single of trading hit 39.66, and the three-weeks RSI is set at 38.28 for Aimmune Therapeutics Inc. [AIMT]. The present Moving Average for the last 50 days of trading for this stock 15.01, while it was recorded at 12.44 for the last single week of trading, and 21.23 for the last 200 days.

Aimmune Therapeutics Inc. [AIMT]: Deeper insight into the fundamentals

Return on Total Capital for AIMT is now -109.36, given the latest momentum, and Return on Invested Capital for the company is -109.33. Return on Equity for this stock declined to -123.33, with Return on Assets sitting at -91.37. When it comes to the capital structure of this company, Aimmune Therapeutics Inc. [AIMT] has a Total Debt to Total Equity ratio set at 51.73. Additionally, AIMT Total Debt to Total Capital is recorded at 34.09, with Total Debt to Total Assets ending up at 26.33. Long-Term Debt to Equity for the company is recorded at 49.56, with the Long-Term Debt to Total Capital now at 32.66.

Reflecting on the efficiency of the workforce at the company, Aimmune Therapeutics Inc. [AIMT] managed to generate an average of -$903,625 per employee.Aimmune Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 7.40 and a Current Ratio set at 7.50.

Earnings analysis for Aimmune Therapeutics Inc. [AIMT]

With the latest financial reports released by the company, Aimmune Therapeutics Inc. posted -1.03/share EPS, while the average EPS was predicted by analysts to be reported at -1.03/share. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for AIMT. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Aimmune Therapeutics Inc. go to 34.60%.

Insider trade positions for Aimmune Therapeutics Inc. [AIMT]

There are presently around $636 million, or 87.20% of AIMT stock, in the hands of institutional investors. The top three institutional holders of AIMT stocks are: PRICE T ROWE ASSOCIATES INC /MD/ with ownership of 5,274,902, which is approximately 1.584% of the company’s market cap and around 0.90% of the total institutional ownership; VANGUARD GROUP INC, holding 4,202,544 shares of the stock with an approximate value of $52.95 million in AIMT stocks shares; and BLACKROCK INC., currently with $49.47 million in AIMT stock with ownership of nearly 8.159% of the company’s market capitalization.

Positions in Aimmune Therapeutics Inc. stocks held by institutional investors increased at the end of July and at the time of the July reporting period, where 97 institutional holders increased their position in Aimmune Therapeutics Inc. [NASDAQ:AIMT] by around 6,511,951 shares. Additionally, 60 investors decreased positions by around 5,697,183 shares, while 31 investors held positions by with 38,269,046 shares. The mentioned changes placed institutional holdings at 50,478,180 shares, according to the latest SEC report filing. AIMT stock had 25 new institutional investments in for a total of 1,831,892 shares, while 25 institutional investors sold positions of 976,747 shares during the same period.

Share on facebook
Share on twitter
Share on linkedin
Share on skype
Share on reddit

Leave a Comment

Your email address will not be published. Required fields are marked *



Download free eBook for 



Get The Best Stocks To Trade Every Day!

Join now to get the pre-market morning brief 100% free

We do not sell or share your information with anyone.